SCHEMBL30337016

SCHEMBL30337016

O=C1NCCc2c1cc(Cl)c(OS(=O)(=O)C(F)(F)F)c2Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.38
PARP10 Q53GL7 10/20 0.35
PARP1 P09874 9/20 0.35
F7 P08709 1/20 0.34
F3 P13726 1/20 0.34
PARP11 Q9NR21 7/20 0.33
PARP15 Q460N3 1/20 0.33
PARP14 Q460N5 1/20 0.33
TIPARP Q7Z3E1 1/20 0.33
PARP16 Q8N5Y8 1/20 0.33
HTT P42858 1/20 0.32
PTK2B Q14289 1/20 0.32
ACHE P22303 1/20 0.31
DAPK3 O43293 1/20 0.31
DYRK3 O43781 1/20 0.31
MAP4K4 O95819 1/20 0.31
CDK1 P06493 1/20 0.31
PIM1 P11309 1/20 0.31
CDK2 P24941 1/20 0.31
CSNK1A1 P48729 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10129818 1.00 MRGPRX4 (0.38) MRGPRX4PARP10PARP1F7F3
SCHEMBL30401909 0.77 PARP1 (0.41) PARP10PARP1F7F3PARP11
SCHEMBL23978726 0.77 PARP1 (0.41) PARP10PARP1F7F3PARP11
SCHEMBL29923807 0.72 CDK2 (0.38) MRGPRX4PARP10PARP1PARP11PARP15
SCHEMBL1417460 0.69 PARP10 (0.51) PARP10PARP1PARP11
SCHEMBL30402278 0.69 ACHE (0.50) PARP10PARP1F7F3PARP11
SCHEMBL10129821 0.69 ACHE (0.50) PARP10PARP1F7F3PARP11
SCHEMBL18305057 0.69 PARP10 (0.57) PARP10PARP1F7F3PARP11
SCHEMBL24916486 0.68 PTGDR2 (0.34) PARP10PARP1PARP11PARP15PARP14
SCHEMBL29923758 0.68 PTGDR2 (0.34) PARP10PARP1PARP11PARP15PARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115916176-A Inhibitors of alpha 2 beta 1 integrin and methods of use thereof 加利福尼亚大学董事会 2023-04-04 CN disclosed